News | Radiopharmaceuticals and Tracers | February 07, 2017

Blue Earth Diagnostics and Siemens' PETNET Solutions Increase Patient Access to Axumin Injection PET Imaging Agent

Agent for imaging of recurrent prostate cancer will be added to several sites in PETNET’s nationwide network throughout 2017

Blue Earth Diagnostics, Axumin, fluciclovine F-18, recurrent prostate cancer, Simens PETNET Solutions, increased patient access

February 7, 2017 — Blue Earth Diagnostics and Siemens’ PETNET Solutions announced that an increasing number of radiopharmacies will offer Blue Earth Diagnostics’ Axumin (fluciclovine F-18) positron emission tomography (PET) imaging agent through PETNET’s national network.

In June 2016, PETNET Solutions began exclusive commercial production and distribution of Axumin at two sites in the United States, and additional sites have been rolled out in subsequent months. There are now 12 metropolitan locations in the United States offering Axumin, including the recent addition of sites in Phoenix, Ariz., and Ft. Lauderdale, Fla., with more sites planned during 2017. Axumin is a novel molecular imaging agent indicated for use in PET imaging to identify suspected sites of prostate cancer recurrence in men who have elevated blood levels of prostate specific antigen (PSA) following prior treatment. It is the first U.S. Food and Drug Administration (FDA)-approved F-18 PET imaging agent indicated for use in patients with suspected recurrent prostate cancer.

Blue Earth Diagnostics CEO Jonathan Allis, D.Phil, announced that Axumin reader training is available in collaboration with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), including a recent live training event at SNMMI’s Mid-Winter Meeting.

According to Allis, the Centers for Medicare and Medicaid Services (CMS) has granted Axumin transitional pass-through payment reimbursement status using a product-specific Healthcare Common Procedure Coding System (HCPCS) A code (A9588), which became effective Jan. 1 of this year.

Prostate cancer is the second leading cause of cancer death in men. While most primary prostate cancer can be successfully treated, recurrence occurs in up to one-third of patients. Recurrent disease is typically detected by a rise in PSA levels, but often the location and extent of the disease cannot be detected by conventional imaging. Of those patients who experience biochemical recurrence, approximately one-third go on to develop metastatic prostate cancer.

For more information: www.blueearthdiagnostics.com, www.usa.healthcare.siemens.com/molecular-imaging/petnet-solutions

Related Content

The FLASH Effect significantly improves the therapeutic ratio for curing cancer

The FLASH Effect significantly improves the therapeutic ratio for curing cancer

News | Radiation Oncology | July 28, 2021
July 28, 2021 — IntraOp Medical Corporation announced that ...
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds

(L-R) Associate Professor Peter Brotchie (St Vincent's), Dr Ruwan Tennakoon (RMIT), Professor John Thangarajah (RMIT), Dr Mark Page (St Vincent's). Image courtesy of St Vincent's Hospital Melbourne

News | Prostate Cancer | July 19, 2021
July 19, 2021 — Prostate cancer is the most diagnosed

Positrigo founders Max Ahnen, Ph.D. (left) and Jannis Fischer, Ph.D.

News | PET Imaging | July 16, 2021
Most countries have not introduced nationwide prostate cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine, indicates that screening by magnetic resonance imaging (MRI) and targeted biopsies could potentially cut overdiagnoses by half.

Getty Images

News | Prostate Cancer | July 12, 2021
July 12, 2021 — Most countries have not introduced nationwide...
American Society for Radiation Oncology (ASTRO) to host in-person Annual Meeting in Chicago, October 24-27

Getty Images

News | ASTRO | July 08, 2021
July 8, 2021 — Registration opens today for the American Society for Radiation Oncology's (...
Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia

Getty Images

News | PET Imaging | July 08, 2021
July 8, 2021 — Biogen and...
The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

Image courtesy of JNM

News | PET Imaging | June 28, 2021
June 28, 2021 — The U.S.
Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others
News | Radiopharmaceuticals and Tracers | June 22, 2021
June 22, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercia
A phase III clinical trial has validated the effectiveness of the prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL in detecting and localizing recurrent prostate cancer.

Figure 1. Case example: A 54-year-old man with a history of RP+LND and a subsequent PSA of 1.25 ng/mL had no evidence of disease by baseline imaging. Piflufolastat F 18 (18F-DCFPyL)- PET/CT accurately detected biochemically recurrent prostate cancer with the PSMA PET/CT scan identifying positive left (left panel) and right peri-rectal lymph nodes (right panel).

News | Prostate Cancer | June 21, 2021
June 21, 2021 — A phase III clinica...